No postoperative survival benefit in concurrent chemoradiation treated patients with low-risk early-stage cervical squamous cell carcinoma
10.3969/j.issn.1000-8179.2013.20130810
- VernacularTitle:同步放化疗对早期低危宫颈鳞癌术后生存无优势
- Author:
Hao YU
;
Linlin ZHANG
;
Xuelian DU
;
Xiugui SHENG
- Publication Type:Journal Article
- Keywords:
cervical squamous cell carcinoma;
radiotherapy;
chemotherapy;
concurrent chemoradiotherapy
- From:
Chinese Journal of Clinical Oncology
2014;46(4):242-245
- CountryChina
- Language:Chinese
-
Abstract:
Objective:The benefits of postoperative adjuvant therapy method for low-risk early-stage cervical squamous cell carcinoma were investigated. Methods:A total of 133 patients with low-risk early-stage cervical squamous cell carcinoma were treated at Shandong Cancer Hospital&Institute from February 2008 to March 2012. All patients received adjuvant therapy:42 were treated with pelvic ra-diotherapy (RT), 47 were treated with adjuvant chemotherapy (CT)+intracavitary radiotherapy (ICRT), and 44 were treated with concurrent chemoradiation (CCRT). Disease-free survival (DFS) and complications of the therapy were evaluated. Results:No significant differences in DFS were observed in the patients treated with RT, CT+ICRT, and CCRT (P>0.05), and the three-year DFS rates were 94.0%, 93.4%, and 97.6%, respectively. The frequencies of grade III to IV acute toxicities were significantly higher in patients treated with CCRT (34.1%) than in those treated with RT (9.5%) or CT+ICRT (16.7%) (P<0.05). No statistically significant difference was observed between the RT group and the CT+ICRT group (P>0.05). Grade I to II late toxicity was significantly more frequent in the CCRT (25%) and RT (19.0%) groups compared with the CT+ICRT group (4.3%) (P>0.05), but no statistically significant differences were observed between the CCRT and the RT groups (P>0.05). Conclusion:CT+ICRT or RT has a three-year DFS rate equivalent to CCRT but with fewer therapy com-plications for low-risk early-stage cervical squamous cell carcinoma.
